On July 30, 2025 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, reported it has received a Notice of Intent to Grant for the European patent application titled, "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE (Press release, Moleculin, JUL 30, 2025, View Source [SID1234654639])." Such grant should solidify the Company’s European Union exclusivity of Annamycin, also known by its non-proprietary name of naxtarubicin, with the potential to become the first non-cardiotoxic anthracycline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The grant is subject to payment of fees and completion of final amendments and formalities. When issued, the patent claims will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term currently extending until into 2040, subject to extension to account for time required to fulfill requirements for regulatory approval. Moleculin’s novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets). Additional preclinical studies performed at a world-renowned cancer center indicate Annamycin may be a potential treatment for many other types of cancers. The new chemical entity uses a unique lipid-based delivery technology and has shown the potential to be used in a wide range of cancers. In addition to the newly expected European patent and previously issued U.S. patents, Moleculin has additional patent applications related to Annamycin pending in the U.S., Europe and in major jurisdictions worldwide.

Walter Klemp, Chairman and CEO of Moleculin, said, "Our preliposomal formulation for Annamycin not only improves the stability and usability of Annamycin, but also creates a scalable platform that has the potential to be a catalyst for how lipophilic oncology drugs are delivered. We are pleased to add this newly granted European patent to our global intellectual property portfolio and believe it provides further validation of Annamycin’s potential. The current patent portfolio includes patents and patent applications with claims to methods of making our preliposomal Annamycin and liposomal Annamycin suspension as well as the resulting compositions for use in the treatment of cancers in the US, Europe, China, and India, among others. We remain committed to fortifying our global patent protection for Annamycin and advancing the development of this potentially transformative therapeutic candidate for hard-to-treat tumors."

Annamycin (naxtarubicin), currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory AML, in addition to Orphan Drug Designation for the treatment of STS lung mets. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the EMA.

On July 30, 2025 Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to VT3989 for the treatment of mesothelioma in the United States (Press release, Vivace Therapeutics, JUL 30, 2025, View Source [SID1234654656]). VT3989, the company’s first-in-class and best-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, is a novel investigational small molecule cancer therapeutic that is designed to target the Hippo pathway by inhibiting palmitoylation of members of the TEAD protein family.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The granting of Orphan Drug Designation to VT3989 underscores the critical need for new, effective therapies for mesothelioma, an aggressive cancer with limited treatment options. The benefits provided by this important designation will support our continued advancement of VT3989, which has already generated compelling clinical trial data, a first for this promising therapeutic class," said Sofie Qiao, Ph.D., president and chief executive officer of Vivace Therapeutics. "We are committed to continuing clinical development of VT3989 and discussing a move into a registrational Phase 3 study in mesothelioma with FDA by the end of 2025."

VT3989 has been evaluated in more than 200 patients to date in an ongoing, open-label Phase 1 clinical study and, to the company’s knowledge, is the first and only member of the TEAD autopalmitoylation inhibitor class for which compelling clinical efficacy data have been publicly reported. In addition to the promising data to date, VT3989 has demonstrated a positive safety profile in the Phase 1 trial, which supports its best-in-class potential.

Clinical findings for VT3989 have been particularly notable in patients with mesothelioma who have failed chemotherapy and immuno-oncology combination regimens, which represent the only approved therapies in this indication. These results will be presented at a major medical conference in the second half of 2025.

Orphan Drug Designation is granted by FDA and is intended to support the development and evaluation of treatments for rare diseases affecting fewer than 200,000 people in the U.S. The designation provides drug developers with potential benefits including tax credits for qualified clinical trials, exemptions from certain FDA fees for clinical trials, and the potential for seven years of market exclusivity following drug approval.

About Phase 1 study of VT3989
The Phase 1 study of VT3989 (View Source) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural and non-pleural malignant mesothelioma.

On July 30, 2025 PharmaMar Group (MSE: PHM) reported an 18% increase in total revenue in the first six months of the year, reaching €95.3 million. Recurring revenue, resulting from the sum of net sales plus royalties received from our partners, grew by 5% as of June 30th, 2025, reaching €72.5 million (Press release, PharmaMar, JUL 30, 2025, View Source [SID1234654640]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the end of the first half of this year, total oncology sales amounted to €45.8 million, representing a 9% increase over the same period last year. These sales include commercial sales of Yondelis (trabectedin) in Europe, sales of raw materials to our partners for both trabectedin and lurbinectedin, distribution of Zepzelca (lurbinectedin) under the compassionate use program ("accès compassionnel"), and commercial sales of lurbinectedin in Switzerland. The increase, during the first half of the year, was driven by the positive performance of lurbinectedin revenues in Europe, where revenues recorded under the compassionate use program – mainly in France – increased by 26% to €15.4 million, as well as commercial sales of lurbinectedin in Switzerland amounting to €8.4 million, representing a growth of 75% compared to the same period in 2024.

At the end of the first half of 2025, oncology royalty income stood at €26.4 million, compared to €26.5 million recorded on June 30th, 2024. This amount corresponds mainly to royalties received from sales of lurbinectedin by our partners Jazz Pharmaceuticals in the US and Luye in China, which together amount to €21.0 million[1], as well as royalties from sales of trabectedin by our partners in the US and Japan, amounting to €5.4 million.

Regarding non-recurring income from licensing agreements, at the end of the first half of 2025, this increased by 87% to €23.0 million, compared to €12.3 million recorded on June 30th, 2024. The increase is driven by the lurbinectedin licensing agreement for Japan signed with Merck for €20.7 million, together with €2.0 million in deferred revenue from the 2019 agreement signed with Jazz Pharmaceuticals in relation to lurbinectedin.

During the first half of the year, €14.7 million was recognized as other net income/(expenses) corresponding to the completed portion of the Syoligo project, for which Sylentis was awarded a grant under the European IPCEI (Important Projects of Common European Interest) ‘Med4Cure’ program for the period January 2023 to August 2026. The total amount of the grant is €21.1 million.

The PharmaMar Group’s investment in R&D amounted to €47.5 million, representing a 7% reduction compared to the first half of 2024, due to the completion of two Phase 3 clinical trials.

Of the total R&D investment for the period, the oncology segment recorded €44.8 million, compared to €46.7 million as of June 30th, 2024. This variation is mainly due to the completion in December 2024 of recruitment for the Phase 3 LAGOON clinical trial with lurbinectedin in small cell lung cancer.

For its part, the RNAi segment recorded €2.7 million in R&D as of June 30th, 2025, compared to €4.6 million for the same period last year. This variation is due to the completion in the first months of 2024 of the Phase 3 PIVO1 clinical trial with tivanisiran for dry eye.

In addition, the Company continues to invest in the clinical development of other molecules at earlier stages. In this regard, two Phase 2 clinical trials are underway with ecubectedin, as well as Phase 1 clinical trials with PM534 and PM54, all for the treatment of solid tumors.

As a result, the PharmaMar Group’s EBITDA reached €25.1 million as of June 30th, 2025, compared to -€0.8 million in the first half of 2024.

The Group’s net profit as of June 30th, 2025, stands at €19.4 million, compared to €3.5 million in the same period last year.

At the end of the first half of the year, the PharmaMar Group had cash and cash equivalents of €128.9 million, with a total financial debt of €48.3 million.

PharmaMar management will host a conference call and webcast for investors and analysts on July 31st, 2025, at 13:00 CET (07:00 AM, New York time) as follows: The numbers to connect to the teleconference are +34 91 901 16 44 (from Spain), +1 646 664 1960 (from USA or Canada), and +44 20 3936 2999 (other countries). Participants’ access code: 883194. Interested parties can also follow the conference call live via the following link: View Source

The recording of the teleconference will be available for thirty days and it can be accessed on PharmaMar’s website by visiting the Events Calendar section of the Company’s website www.pharmamar.com

On July 30, 2025 Akeso, Inc. (9926.HK) ("Akeso" or the "Company") reported that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy (Press release, Akeso Biopharma, JUL 30, 2025, View Source;therapy-for-immunotherapy-resistant-nsclc-302518092.html [SID1234654657]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ivonescimab is the only bispecific immunotherapy antibody currently undergoing Phase III registration trials for IO-resistant lung cancer.

In recent years, immunotherapy has achieved significant progress in the treatment of NSCLC. PD-1/L1 inhibitors, whether used as monotherapy or in combination with platinum-based chemotherapy, have become the standard first-line treatment for advanced NSCLC in patients without driver mutations. However, despite these advances, 60%-70% of patients experience disease progression within the first year of treatment.

Currently, there are no approved standard treatment options for IO-resistant NSCLC. Docetaxel is recommended in both China’s and international treatment guidelines for immunotherapy-resistant (IO-resistant) NSCLC. However, docetaxel’s monotherapy efficacy in the IO-resistant NSCLC patients remains limited. Several Phase III clinical trials investigating IO-resistant lung cancer, including immunotherapy combination therapies studies and ADC therapy studies, have failed to demonstrate positive results.

Mechanistic studies suggest that PD-1 therapy can restore the immune system’s anti-tumor activity, while anti-VEGF therapy alleviates VEGF-mediated immune suppression and promotes T-cell infiltration. When combined, these two therapies may produce synergistic effects. Ivonescimab simultaneously targets both PD-1 and VEGF pathways, reversing the immune-suppressive tumor microenvironment and reactivating anti-tumor immune responses. These synergistic mechanisms provide a scientific rationale for using ivonescimab to treat IO-resistant tumors. Furthermore, the positive efficacy and safety data demonstrated in a Phase II study in this indication underscore the significant therapeutic potential of ivonescimab in this difficult to treat patient population.

The ivonescimab regimen has demonstrated remarkable efficacy and excellent safety across multiple tumor types. The ongoing AK112-305/HARMONi-8A Phase III study targeting IO-resistant NSCLC is expected to offer a novel and highly effective treatment option for patients with IO-resistant NSCLC, in line Akesos ‘ ‘Immuno-2.0’ strategy.

As the world’s leading PD-1/VEGF bispecific antibody, ivonescimab has achieved extensive population coverage for core indications in NSCLC and is positioned across multiple lines of treatment, with the potential to reshape the overall treatment landscape for advanced NSCLC.

On July 30, 2025 Takeda reported financial report for the quarter ended June 30, 2025 (Presentation, Takeda, JUL 30, 2025, View Source [SID1234654685]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!